Funder: METAvivor
Due Dates: March 12, 2025 (Letter of Intent) | August 20, 2025 (Invited Full Application) | December 30, 2025 (Funding Organization's Deadline)
Funding Amounts: Up to $200,000 total over two years; includes direct costs, up to $3,000 for travel, and up to 5% indirect costs.
Summary: Supports innovative research by early-career investigators to advance understanding and treatment of metastatic (stage IV) breast cancer.
Key Information: Project must focus on established metastatic breast cancer; prevention or general diagnosis studies are not eligible.